We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$8.02B
AUM Growth
+$201M
(+2.6%)
Cap. Flow
-$89M
Cap. Flow
% of AUM
-1.11%
Top 10 Holdings %
Top 10 Hldgs %
19.81%
Holding
867
New
76
Increased
308
Reduced
302
Closed
63
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$48.8M |
| 2 |
Procter & Gamble
PG
|
+$24.6M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$23.6M |
| 4 |
Keysight
KEYS
|
+$23.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$21.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$46.5M |
| 2 |
ExxonMobil
XOM
|
+$36.6M |
| 3 |
GG
Goldcorp Inc
GG
|
+$24.9M |
| 4 |
Walt Disney
DIS
|
+$23.8M |
| 5 |
NAVG
Navigators Group Inc
NAVG
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.16% |
| 2 | Technology | 16.87% |
| 3 | Financials | 10.38% |
| 4 | Consumer Discretionary | 9.09% |
| 5 | Communication Services | 7.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Charter Communications
CHTR
$14.7B
| $11M | 0.14% |
28,054
-1,276
| -4% | -$478K |
|
|
FOLD
177
DELISTED
Amicus Therapeutics
FOLD
| $11M | 0.14% |
886,000
+150,000
| +20% | +$1.9M |
|
178
Ameriprise Financial
AMP
$46.8B
| $11M | 0.14% |
65,778
-12,686
| -16% | -$1.83M |
|
179
Universal Display
OLED
$3.71B
| $11M | 0.14% |
58,489
+915
| +2% | +$152K |
|
|
APC
180
DELISTED
Anadarko Petroleum
APC
| $10.8M | 0.14% |
154,072
+37,672
| +32% | +$2.53M |
|
181
Ametek
AME
$55.5B
| $10.7M | 0.13% |
118,559
+89,120
| +303% | +$7.64M |
|
182
Electronic Arts
EA
$52.4B
| $10.7M | 0.13% |
106,365
+33,360
| +46% | +$3.18M |
|
183
United Parcel Service
UPS
$97.6B
| $10.6M | 0.13% |
93,372
-856
| -0.9% | -$89K |
|
184
lululemon athletica
LULU
$13B
| $10.6M | 0.13% |
58,970
+38,771
| +192% | +$6.73M |
|
185
HP
HPQ
$23.5B
| $10.5M | 0.13% |
178,198
-21,054
| -11% | -$416K |
|
186
Halozyme
HALO
$9.72B
| $10.4M | 0.13% |
610,079
+19,500
| +3% | +$315K |
|
|
CMA
187
DELISTED
Comerica
CMA
| $10.3M | 0.13% |
141,745
-19,688
| -12% | -$1.46M |
|
188
Lincoln National
LNC
$7.91B
| $10.1M | 0.13% |
157,473
+20,453
| +15% | +$1.31M |
|
|
IMMU
189
DELISTED
Immunomedics Inc
IMMU
| $10.1M | 0.13% |
730,400
-205,487
| -22% | -$3.09M |
|
|
EIDX
190
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $9.99M | 0.12% |
323,000
-102,000
| -24% | -$2.77M |
|
|
SPLK
191
DELISTED
Splunk Inc
SPLK
| $9.91M | 0.12% |
79,182
-2,594
| -3% | -$330K |
|
|
DRNA
192
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-447,500
| Closed | -$6.09M |
|
193
Tesla
TSLA
$1.24T
| $9.78M | 0.12% |
659,310
-12,315
| -2% | -$192K |
|
194
Costco
COST
$415B
| $9.74M | 0.12% |
37,009
+3,486
| +10% | +$869K |
|
195
Toronto Dominion Bank
TD
$198B
| $9.71M | 0.12% |
166,476
-44,367
| -21% | -$2.5M |
|
196
General Mills
GIS
$19.2B
| $9.64M | 0.12% |
184,342
-56,873
| -24% | -$2.94M |
|
|
RHT
197
DELISTED
Red Hat Inc
RHT
| $9.63M | 0.12% |
51,487
+2,427
| +5% | +$448K |
|
198
GE Aerospace
GE
$367B
| $9.54M | 0.12% |
168,267
-39,288
| -19% | -$1.93M |
|
199
Dollar General
DG
$25.9B
| $9.49M | 0.12% |
70,512
+23,082
| +49% | +$2.92M |
|
200
Travelers Companies
TRV
$80.8B
| $9.43M | 0.12% |
56,310
-39,551
| -41% | -$5.7M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2019 Portfolio in Review
As of Q2 2019, Candriam SCA held 867 positions worth $8.02B, up 2.6% from $7.82B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Candriam SCA's Q2 2019 filing shows 76 new, 308 increased, 302 reduced and 63 closed positions. Its largest new stake was Total System Services, Inc.: 112,342 shares worth $14.3M. The largest sale was Celgene Corp, an estimated $46.5M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
- Candriam SCA's largest Q2 2019 buy was Total System Services, Inc.: 112,342 shares worth $14.3M.
- Candriam SCA added most to Vertex Pharmaceuticals in Q2 2019, an estimated $48.8M increase.
- Candriam SCA's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $46.5M.
- Candriam SCA fully exited Goldcorp Inc in Q2 2019, selling an estimated $24.9M.
- Candriam SCA's ten largest holdings make up 20% of its $8.02B portfolio in Q2 2019.
- Candriam SCA opened 76 new positions and closed 63 in Q2 2019.
- Candriam SCA's portfolio value rose 2.6% quarter-over-quarter to $8.02B.
Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.